UNSPSC 51162022: Ephedrine/guaifenesin/theophylline

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162022 Ephedrine/guaifenesin/theophylline is a Commodity code whose nominal scope does not align with the actual state and local procurement activity recently tagged to it. The two most recent opportunities posted under this code involve naloxone procurement and on-site pharmacy services — neither of which involves the pharmaceutical combination named in the code. Seminole County, Florida sought 1,900 units of naloxone and 800 safe drug deactivation systems annually via IFB, while Hall County, Georgia issued an RFQ/P for on-site pharmacy services serving approximately 3,000 employees and dependents enrolled in the county's group health insurance plans. The mismatch suggests either miscoding at the issuing-body level or that the code is being used as a catchall for pharmaceutical procurement more broadly.

Activity under this code is sparse and geographically limited to Florida and Georgia in the recent record. Seminole County's naloxone procurement (IFB 60459723LAS, response deadline July 26, 2023) required quarterly deliveries and included FEMA compliance provisions. Hall County's pharmacy services RFQ/P #47-010 (due June 4, 2026) specified a 25-medication formulary, an 80/20 technical-to-cost evaluation weighting, and an initial one-year term with four optional one-year renewals beginning January 1, 2027. Neither opportunity specified set-aside designations. The code shows limited recent purchasing momentum, and practitioners should verify code alignment with issuing bodies before pursuing opportunities, particularly when the posted solicitation title diverges from the code's stated pharmaceutical scope.